Neurizon Completes Entitlement Offer

• $5.88 million raised through well-supported Entitlement Offer
• Strong participation from Eligible Shareholders and oversubscriptions
• Proceeds to support regulatory, manufacturing and operational activities for HEALEY ALS Platform Trial

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced the results of its pro-rata non-renounceable entitlement offer. The Entitlement Offer, which closed on January 21, 2026, was well supported by eligible shareholders who applied for 59,524,761 new shares under the offer and an additional 13,983,956 new shares under the oversubscription facility, raising a total of $5,880,697.36 (before costs). The proceeds from the Entitlement Offer will strengthen Neurizon's balance sheet and provide additional flexibility as the company progresses regulatory, manufacturing and operational activities in preparation for the first patient dosing in the HEALEY ALS Platform Trial, targeted for Q1 CY2026. Sergio Duchini, Chairman of the Board and Non-Executive Director at Neurizon, commented that the strong shareholder support reinforces confidence in the company's strategy, execution discipline and long-term vision. Neurizon remains focused on disciplined execution of its clinical development, with a primary focus on advancing NUZ-001 within the HEALEY ALS Platform Trial.